These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12088781)

  • 1. Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I).
    Murphy SA; Gibson CM; Van de Werf F; McCabe CH; Cannon CP
    Am J Cardiol; 2002 Jul; 90(1):51-4. PubMed ID: 12088781
    [No Abstract]   [Full Text] [Related]  

  • 2. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
    Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E
    Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
    Dunn CJ; Goa KL
    Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial.
    Angeja BG; Alexander JH; Chin R; Li X; Barron HV; Armstrong PW; Granger CB; Van de Werf F; Gibson CM
    Am J Cardiol; 2001 Dec; 88(11):1240-5. PubMed ID: 11728350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes.
    Mehta RH; Alexander JH; Van de Werf F; Armstrong PW; Pieper KS; Garg J; Califf RM; Granger CB
    JAMA; 2005 Apr; 293(14):1746-50. PubMed ID: 15827313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
    Sinnaeve P; Alexander J; Belmans A; Bogaerts K; Langer A; Diaz R; Ardissino D; Vahanian A; Pehrsson K; Armstrong P; Van de Werf F;
    Am Heart J; 2003 Jul; 146(1):27-32. PubMed ID: 12851604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
    Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
    Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
    ; Van De Werf F; Adgey J; Ardissino D; Armstrong PW; Aylward P; Barbash G; Betriu A; Binbrek AS; Califf R; Diaz R; Fanebust R; Fox K; Granger C; Heikkilä J; Husted S; Jansky P; Langer A; Lupi E; Maseri A; Meyer J; Mlczoch J; Mocceti D; Myburgh D; Oto A; Paolasso E; Pehrsson K; Seabra-Gomes R; Soares-Piegas L; Sùgrue D; Tendera M; Topol E; Toutouzas P; Vahanian A; Verheugt F; Wallentin L; White H
    Lancet; 1999 Aug; 354(9180):716-22. PubMed ID: 10475182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.
    Modi NB; Fox NL; Clow FW; Tanswell P; Cannon CP; Van de Werf F; Braunwald E
    J Clin Pharmacol; 2000 May; 40(5):508-15. PubMed ID: 10806604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
    Curtis JP; Alexander JH; Huang Y; Wallentin L; Verheugt FW; Armstrong PW; Krumholz HM; Van de Werf F; Danays T; Cheeks M; Granger CB;
    Am J Cardiol; 2004 Aug; 94(3):279-83. PubMed ID: 15276088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
    Sinnaeve PR; Alexander JH; Bogaerts K; Belmans A; Wallentin L; Armstrong P; Adgey JA; Tendera M; Diaz R; Soares-Piegas L; Vahanian A; Granger CB; Van De Werf FJ
    Am Heart J; 2004 Jun; 147(6):993-8. PubMed ID: 15199346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators.
    Gibson CM; Cannon CP; Murphy SA; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Fox NL; Berioli S; Weaver WD; Van de Werf F; Braunwald E
    Am J Cardiol; 1999 Nov; 84(9):976-80. PubMed ID: 10569649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of tenecteplase in acute myocardial infarction.
    Iavelov IS
    Kardiologiia; 2007; 47(1):37-46. PubMed ID: 17431964
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.
    Tanswell P; Modi N; Combs D; Danays T
    Clin Pharmacokinet; 2002; 41(15):1229-45. PubMed ID: 12452736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does a single bolus thrombolytic reduce door to needle time in a district general hospital?
    Leah V; Clark C; Doyle K; Coats TJ
    Emerg Med J; 2004 Mar; 21(2):162-4. PubMed ID: 14988339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
    Antman EM; Louwerenburg HW; Baars HF; Wesdorp JC; Hamer B; Bassand JP; Bigonzi F; Pisapia G; Gibson CM; Heidbuchel H; Braunwald E; Van de Werf F
    Circulation; 2002 Apr; 105(14):1642-9. PubMed ID: 11940541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction: the Athens PCI trial.
    Kanakakis J; Nanas JN; Tsagalou EP; Maroulidis GD; Drakos SG; Ntalianis AS; Tzoumele P; Skoumbourdis E; Charbis P; Rokas S; Anastasiou-Nana M
    Catheter Cardiovasc Interv; 2009 Sep; 74(3):398-405. PubMed ID: 19360864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of tenecteplase in acute myocardial infarction.
    Guerra DR; Karha J; Gibson CM
    Expert Opin Pharmacother; 2003 May; 4(5):791-8. PubMed ID: 12740001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction.
    Roe MT; Green CL; Giugliano RP; Gibson CM; Baran K; Greenberg M; Palmeri ST; Crater S; Trollinger K; Hannan K; Harrington RA; Krucoff MW;
    J Am Coll Cardiol; 2004 Feb; 43(4):549-56. PubMed ID: 14975462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing regimen of reteplase and costeffectiveness.
    Hödl R; Kraxner W; Maier R; Klein W
    Lancet; 2001 Oct; 358(9291):1462. PubMed ID: 11705534
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.